Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-TEC nasal chondrocyte-based engineered cartilage implantation for patellofemoral osteoarthritis
2023-508640-21-00Phase 2Authorised
- Sponsor
- University Hospital Basel
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised trial of rimegepant in Patellofemoral Arthritis (2 arms), sponsored by University Hospital Basel. Primary endpoint: Primary: KOOS Pain change at 24 months. Planned start Sep 2025; status: authorised.
02
Drugs
rimegepant
03
Conditions
Patellofemoral Arthritis
Beyond the preview
Go deeper on 2023-508640-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508640-21-00.